Volume 11, Issue 6 (9-2013)                   IJRM 2013, 11(6): 473-0 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nikbakht Dastjerdi M, Aboutorabi R, Eslami Farsani B. Association of TP53 gene codon 72 polymorphism with endometriosis risk in Isfahan. IJRM 2013; 11 (6) :473-0
URL: http://ijrm.ir/article-1-431-en.html
1- Department of Anatomical Sciences and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran , nikbakht@med.mui.ac.ir
2- Department of Anatomical Sciences and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Full-Text [PDF 310 kb]   (532 Downloads)     |   Abstract (HTML)  (2064 Views)
Full-Text:   (269 Views)
Introduction
 
Endometriosis is one of the most common gynecological problems in women. It has the same features of malignant tumors and its cause is unknown. Almost 10% of women suffer from this disease and it is seen in 18% of women during the reproductive years (1, 2). This ratio reaches to nearly 30-40% in infertile women (3). Endometriosis has been occurred by growing endometrial tissues outside the uterus and causes the abnormalities like painful sexual intercourse, painful menstruation, pelvic pains and infertility (4-7).
For explaining the cause of the disease, theory of retrograde menstruation is the most widely accepted theory. It suggests that some endometrial debris exit the uterus through the fallopian tubes and aggregate with each other on the peritoneal surface where it can proceed to invade the tissue as endometriosis (8). This event occurs during a woman's menstrual flow. Some of genetic deficits may have the role in making disease (9). It is determined that the chromosome 17 may be impaired in this disease, because TP53 gene as the most important tumor suppressor gene that is located on short arm of chromosome 17 (10-12).
The genetic instability of cancer cells is a common event which is caused by aneuploidy and gene mutation. Chromosome 17 aneuploidy had occurred during the development of cancer. The product of the TP53 gene, has named p53 protein. This protein participates in cell cycle regulation, apoptosis, DNA repair, and angiogenesis and is mutated in more than 50% of all cancers (13, 14). The TP53 gene consists of 11 exons and 10 introns and has a high frequency of mutations and polymorphisms (15).
Because endometriosis is believed to be a multifactorial illness and its frequency show a discrepancy, there is a necessity for persisted study to recognize polymorphisms that are related with the incidence of endometriosis and its unreliable medical stages. Even though it is indistinct which TP53 gene polymorphism is accountable for changes in p53 protein action, a number of researches have revealed that polymorphisms in intron 3 and exon 4 are concerned in the growth of a variety of diseases (16).
It have showed that structural alterations in the p53 protein can outcome from a single amino acid exchange that causes improper protein action and defeat of role because of an incapability to cooperate with further transcription factors for transcription. These changes can cause carcinogenesis and cancer development (16). It is determined that codon 72 exon 4 TP53 gene has epidemic polymorphism that may produce two alleles. One allele is Arginine (Arg) with the sequence of CGC and other one is Proline (Pro) with sequence of CCC. According to the possibility of existing these alleles, it is possible to create three different genotypes such as Arg/Arg, Pro/Arg, Pro/Pro (16-24).
The codon 72 polymorphism is placed in a SH3-binding domain site, which is necessitated for development repression and apoptosis arbitrated by p53 but not for cell cycle stop (16). The proteins p53Arg72 and p53Pro72 have dissimilar biochemical and biological possessions for example dissimilarity in the binding to parts of the transcriptional apparatus and dissimilarity in the initiation of transcription (17). The p53Arg72 protein persuades apoptosis quicker and represses alteration more competently than the p53Pro72 protein (17, 18).
Because of efficient divergences between the two polymorphic alternatives of TP53, genotype at codon 72 could change susceptibility to endometriosis growth. The function of codon 72 polymorphism of TP53 gene had been noticed in the patients with endometrosis in several populations even though the outcomes are still contentious (25-32). It had been shown that the codon 72 polymorphism in different geographic and ethnic populations have different effects on disease (19). However, the function of the polymorphism concerning endometriosis risk in the Isfahanian population has not been accounted.
This study discovers a probable relationship between endometriosis and this polymorphism in a minor population choosed from Isfahan metropolis.

Materials and methods
 
This cross-sectional study was conducted between February 2010 and august 2011 in Shahid Beheshti, Mehregan and Alzahra hospitals of Isfahan and Department of Anatomy and Molecular Biology of Isfahan University of Medical Sciences. Samples were divided into two groups: 1) endometriosis (n=90); and 2) nonendometriosis group (n=90). The non-endometriosis statuses as control group were confirmed during the cesarean section or diagnostic laparoscopy.
In endometriosis group, women with surgically and histologically diagnosed endometriosis were included, the criterion to enter the study was confirmation which obtained from pathologist and gynecologist in diagnosis of endometriosis, stage II to stage IV. Stage I or minimal (mild endometriosis) excluded from this study since this stage could be observed in asymptomatic women and maybe considered as normal physiological process. Again the cases with structural abnormality in genital system, hypertensive and diabetic women were excluded from our study. Informed consent was obtained from each woman after a brief and clarified explanation was given to them on why their samples are being obtained for this study.
The Ethics Committee of Isfahan University of Medical Sciences approved this study. After gathering the samples, DNA was extracted by standard methods as described previously (33). In the next stage, amplifi­cation of exon 4 of TP53 was performed using Alle-specific PCR with the following primers: 5'-TTGCCGTCCCAAGCAATGGATGA-3' and 5'-TCTGGGAAGGGACAGAAGATGAC-3' (Pairs of specific primers for Arginine) or 5′GCCAGAGGCTGCTCCCCC-3' and 5′-CGTGCAAGTCACAGACTT-3' (Pairs of specific primers for Proline) (18). Among 100-300 nanograms DNA was utilized as template in a 25 µL PCR reaction combination including 1.5 µmol MgCl2, 1 U Taq polymerase (Sinagen, Iran) and 2 µmol either of the primer pairs.
PCR cycling circumstances were carried out with an early denaturation step for 3 min at 94oC, followed by 35 cycles of 30 s at 94oC, 30 s at 60oC (for Arg) or 54oC (for Pro) and    30 s at 72oC. A finishing extension step was executed at 72oC for 5 min. The PCR reaction was done individually for each of the two polymorphic variants. The amplified outcomes were subjected to electrophoresis on 1% agarose gel in 1×TBE buffer and visualized on a transilluminator by means of ethidium bromide. We used a PCR 50 bp Ladder in exact 100 bp spaced recombinant repeats (Sinagen, Iran).
 
Statistical analysis
Obtained information via software SPSS version 20 have been analyzed. For comparing the frequency distribution of three different genotype of codon 72 in endometriosis samples with that of control ones, Chi-Square Test has been used.         P-value less than 0.05% is considered meaningful.
 
Results
 
The ages of samples were between 23-50 years old. To analyze the codon 72 polymorphism, we used a PCR-based assay that specifically, amplify either TP53 Pro or TP53 Arg allele and give a PCR product by using specific primers for Arg allele and/or Pro allele respectively. Consequential PCR products were either 141bp (Figure 1) for Arg allele or 177bp (Figure 2) for Pro allele.
TP53 codon 72 polymorphism was successfully detected by allele -specific PCR in all cases and controls. The distribution of the three different genotypes of codon 72 in exon 4 of TP53 in our cases and controls is shown in table I. In control samples, the genotype distribution for p53 polymorphism showed 42.2%, 54.4% and 3.3% for the Arg/Arg, Arg/Pro and Pro/Pro genotypes, respectively. In the endometriosis group 28.9% of the cases were Arg/Arg, 55.6% were Arg/Pro and 15.6% were Pro/Pro (Table I). A significant difference between cases and controls was found for the Pro/Pro genotype compared with (grouped) Arg/Pro and Arg/Arg genotypes (OR=5.34 (1.47-19.29), p=0.009).
 

Table I. Genotypic frequency distribution in control and endometriosis group





Figure 1. Agarose gel electrophoresis for Arginine allele: samples 2-4 have the band (141bp). Lane 5 is ladder and lane 1 is negative control. Present bands in the end of lanes are primer dimmer.



Figure 2. Agarose gel electrophoresis for Proline allele (171bp): samples 2-4 and 6 have the band and sample 5 has not the band. Lane 7 is ladder and lane1 is negative control. Present bands in the end of lanes are primer dimmer.


Discussion
 
In this study, we found a difference in frequency distribution of genotype between control and endometriosis. Frequency of genotype Arg/Pro in patient group is 55.6% in comparison with 54.4% in healthy group. Frequency of genotype Arg/Arg in patient group is 28.9% in comparison with 42.2% in healthy group. Frequency of genotype Pro/Pro in patients group is 15.6% in comparison with 3.3% in healthy group.  Therefore, results of this study showed that Pro/Pro genotype can be considered as probable risk of endometriosis in Isfahan [p=0.009, CI: 95%, OR=5.34 (1047-19.29)].
This finding is compatible with the result representing the situation of Chinese population by the Change et al and also Lattuada’s group in the Milan city (26, 32). Chang and his colleagues reported that there is a relationship between Pro allele and endometriosis among Chinese population. The proportions of Arg homozygotes, heterozygote, and Pro homozygotes in the endometriosis and nonendometriosis groups in their study were 10.2%, 66.9%, 22.9% and 30.7%, 50%, and 19.3%, respectively. The study has been conducted on a group of Milanese people in Italy, Lattuada and his colleagues found highest frequency of Proline allele in more critical kinds (26).
The respective proportions of arginine homozygotes, heterozygotes and proline homozygotes in their study were 55.6, 39.7 and 4.6% in the group with endometriosis and 59.9, 30.9 and 9.2% in the control group. Also Ammendola et al studied the interaction between TP53 and PTPN22 and found that the Arg genotype showed a protective effect against endometriosis in carriers of the T allele of PTPN22 (27). In the study of Brazilian women, Ribeiro Júnior and his colleagues found a significant association between the heterozygous and homozygous proline genotypes and intense pain in the patients (28).
Ghasemi et al reported an increased frequency of the Pro allele in Iranian women with endometrial cancer and observed that in infertile women with endometriosis, Pro allele is very common (29). The respective proportions of arginine homozygotes, heterozygotes and proline homozygotes in their study were 7, 50 and 43% in the group with endometriosis and 12, 66 and 22% in the control group. These studies showed an association between the Pro/Pro and heterozygote genotypes of the TP53 gene and endometriosis. Homozygous genotype Arg/Arg in codon 72 has low aptitude to suffer endometriosis, as homozygous or heterozygous allele of Pro has higher aptitude to suffer endometriosis.
Endometriosis occurs in roughly 6-10% of women. This ratio is 30-40% in infertile women (1). A number of histopathological studies point that endometriosis might be the neoplastic procedure leading to endometrial ovarian and clear cell carcinoma, most expected resulting from accelerated propagation of endometrial glands and stroma exterior of the uterine cavity (34, 35).
The TP53 tumor suppressor gene holds a high incidence of missense mutations that are chiefly established in the central DNA-binding domain that can change gene regulation and protein levels and influence cell development, DNA repair, and apoptosis and endorse carcinogenesis (16). Molecular mutations like polymorphism of TP53 relate to growing and developing this disease. Natural role of protein P53 is to protect genome against received damages and leads to repair genome and /or apoptosis (15).
Recently, a number of studies have investigated genetic polymorphisms as a possible factor contributing to the development of endometriosis. The relationship between TP53 gene polymorphisms and endometriosis is contentious; some researches account a negative relationship between endometriosis risk and the TP53 codon 72 polymorphism. These researches propose that this negative connection is affected by ethnical variations (36).
Other researches propose an enhanced risk of endometriosis in patients with the TP53 codon 72 polymorphism (26-32). Our results suggest that the frequencies of TP53 codon 72 Pro/Pro and Arg/Pro genotypes are significantly different between control women and endometriosis patients. So, these data indicate that the proline allele of codon 72 TP53 polymorphism might be a good marker for endometriosis patients in the Isfahanian population. The proline allele of codon 72 polymorphism might influence mRNA splicing and influence gene expression and DNA-protein communications.
This might produce changes in the endometrial tissue, and when paired with oxidative stress, may participate a central position in the inflammatory response of endometriosis, proposed that the increase of pro-oxidant things as the heme group and iron present in retrograde menstruation and ovarian hemorrhage can effect in toxicity and probably play a part to endometriosis and the succeeding malignant alteration (34). Unlike mentioned repots, recent results of Omori et al have not found the relation between endometriosis and polymorphism of codon pro72 (25). In their report, the percentages of Arg homozygotes/ heterozygotes/ Pro homozygotes in endometriosis and control groups were 35.2/48.6%/16.2% and 39.4/41.7/18.9%, respectively.
This inconsistency may be because of racial difference. In another study, metaanalyses discovered that persons with the Pro-carriers had increased risk of endometriosis (OR=2.595, 95%; CI:1.005-6.702, p=0.049) in Asian, but not in Caucasian (OR=1.005, 95%; CI:0.755-1.337, p=0.972) (31). So, the differences in ethnicity may be one major cause for the disagreement a variety of speculations attempt to clarify the mechanism of endometriosis. However, further studies with greater sample size is necessary, along with regard to other factors that can weaken the immune system such as smoking, diet and susceptible to certain diseases.
 
Acknowledgments
 
We appreciate honorable staff of Molecular Anatomy and Biology Departmnet specially Mrs. Zahra Safi Zadeh who contribute us to collect endometriosis specimens. This work was supported by deputy for Research Isfahan University of Medical Sciences (grant number 389076).
 
Conflict of interest
 
The authors declare no conflict of interest in results.
 
Type of Study: Original Article |

References
1. Molgaard CA, Gresham L, Golbeck AL. Current concepts in endometriosis. West J Med 1985; 143: 42-46.
2. Wieser F, Schneeberger C, Tong D, Tempfer C, Huber JC, Wenzl R. PROGINS receptor gene polymorphism is associated with endometriosis. Fertil Steril 2002; 77: 309-312. [DOI:10.1016/S0015-0282(01)02984-3]
3. Strathy JH, Molgaard CA, Coulam CB, Melton LJ 3rd. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril 1982; 38: 667-672. [DOI:10.1016/S0015-0282(16)46691-4]
4. Wong WSF, Lim CED. Hormonal treatment for endometriosis associated pelvic pain. Iran J Reprod Med 2011; 9: 163-170.
5. Seifati SM, Parivar K, Aflatoonian A, Dehghani Firouzabadi R, Sheikhha MH. No association of GSTM1 null polymorphism with endometriosis in women from central and southern Iran. Iran J Reprod Med 2012; 10: 23-28.
6. Shahrokh Tehrani Nejad E, Hoseini Rashidi B, Larti A, Ezabadi Z, Jahangiri N, Azimi Nekoo E. The outcome of in vitro fertilization/ intracytoplasmic sperm injection in endometriosis-associated and tubal factor infertility. Iran J Reprod Med 2009; 7: 1-5.
7. Ghahiri A, Najafian A, Ghasemi M, Najafian A. Comparison study on effectiveness of pentoxifyllin with LD to prevent recurrent endometriosis. Iran J Reprod Med 2012; 10: 219-222.
8. Seli E, Berkkanoglu M, Arici A. Pathogenesis of endometriosis. Obstet Gynecol Clin North Am 2003; 30: 41-61. [DOI:10.1016/S0889-8545(02)00052-9]
9. Treloar SA, O'Connor DT, O'Connor VM, Martin NG. Genetic influences on endometriosis in an Australian twin sample. Fertil Steril 1999; 71: 701-710. [DOI:10.1016/S0015-0282(98)00540-8]
10. Kosugi Y, Elias S, Malinak LR, Nagata J, Isaka K, Takayama M, et al. Increased heterogeneity of chromosome 17 aneuploidy in endometriosis. Am J Obstet Gynecol 1999; 180: 792-797. [DOI:10.1016/S0002-9378(99)70649-6]
11. Chang FH, Tzeng DS, Lee TM, Chen TC, Hsu LS, Lung FW. Mutations in the p53 tumor suppressor gene in colorectal cancer in Taiwan. Kaohsiung J Med Sci 2003; 19:151-158. [DOI:10.1016/S1607-551X(09)70464-4]
12. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331. [DOI:10.1016/S0092-8674(00)81871-1]
13. Vogelstein B Cancer. A deadly inheritance. Nature 1990; 348: 681-682. [DOI:10.1038/348681a0]
14. Harris CC, Hollstein M. Clinical implications of the P53 tumor suppressor gene. N Engl J Med 1993; 329: 1318-1327. [DOI:10.1056/NEJM199310283291807]
15. Knudson AG. Hereditary cancer, oncogens, and antioncogenes. Cancer Res 1985; 45: 1437-1443.
16. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092-1100. [DOI:10.1128/MCB.19.2.1092]
17. Doosti A, Zamani M, Ghasemi Dehkordi P, Taheri Sh, Banitalebi M, Mahmoudzadeh M. Association of the p53 codon 72 polymorphism with colorectal cancer in South West of Iran. Sci Res Essays 2011; 6: 3148-3152.
18. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-234. [DOI:10.1038/30400]
19. Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 1997; 4: 239-245.
20. Nikbahkt Dastjerdi M. TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan. Acta medica Iranica 2011; 49: 71-77.
21. Nikbahkt Dastjerdi M, Mirmohammad Sadeghi H. TP53 Codon 72 Heterozygosity May Promote Microsatellite Instability in Sporadic Colorectal Cancer. Yakhteh 2010; 12: 25-32.
22. Nikbahkt Dastjerdi M, Salehi M, Mohajeri M R, Morsali F, Mirmohammad Sadeghi H, Esfandiary E. Evidence for an association of TP53 codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan. JRMS 2008; 13: 317-323.
23. Nikbakht Dastjerdi M, Hasanzadeh M, Talebi A, Akbari M. Investigation of P53 Codon 72 Polymorphism in Patients with Nonmelanoma Skin Cancers in Isfahan. J Isfahan Med School 2011; 29: 679-684.
24. Faghani M, Nikbahkt M, Salehi M, Rabbani M, Talebi A, Soleimani B, et al. Study of p53 polymorphism at codon 72 in patients of breast cancer in Isfahan. J Isfahan Med School 2007; 25: 679-685.
25. Omori S, Yoshida S, Kennedy SH, Negoro K, Hamana S, Barlow DH, et al. Polymorphism at codon 72 of the p53 gene is not associated with endometriosis in a Japanese population. J Soc Gynecol Invest 2004; 11: 232-236. [DOI:10.1016/j.jsgi.2003.11.004]
26. Lattuada D, Viganò P, Somigliana E, Abbiati A, Candiani M, Di Blasio AM. Analysis of the codon 72 polymorphism of the TP53 gen in patients with endometriosis. Mol Hum Reprod 2004; 10: 651-654. [DOI:10.1093/molehr/gah093]
27. Ammendola M, Gloria-Bottini F, Sesti F, Piccione E, Bottini E. Association of P53 codon 72 Polymorphism with endometriosis. Fertil Steril 2008; 90: 406-408. [DOI:10.1016/j.fertnstert.2007.06.051]
28. Ribeiro Júnior CL, Arruda JT, Silva CT, Moura KK. Analysis of p53 codon 72 gene polymorphism in Brazilian patients with endometriosis. Genet Mol Res 2009; 8: 494-499. [DOI:10.4238/vol8-2gmr593]
29. Ghasemi N, Karimi-Zarchi M, Mortazavi-Zadeh MR, Atash-Afza A. Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer. Cancer Genet Cytogenet 2010; 196: 167-170. [DOI:10.1016/j.cancergencyto.2009.09.013]
30. Gallegos-Arreola MP, Figuera-Villanueva LE, Puebla-Pérez AM, Montoya-Fuentes H, Suarez-Rincon AE, Zú-iga-González GM. Association of TP53 gene codon 72 polymorphism with endometriosis in Mexican women. Genet Mol Res 2012; 11: 1401-1408. [DOI:10.4238/2012.May.15.10]
31. Jia S, Xu L, Chan Y, Wu X, Yang S, Yu H, et al. p53 codon 72 polymorphism and endometriosis: a meta-analysis. Arch Gynecol Obstet 2012; 285: 1657-1661. [DOI:10.1007/s00404-012-2226-5]
32. Chang CC, Hsieh YY, Tsai FJ, Tsai CH, Tsai HD, Lin CC. The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril 2002; 77: 43-45. [DOI:10.1016/S0015-0282(01)02938-7]
33. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215. [DOI:10.1093/nar/16.3.1215]
34. Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, et al. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep 2009; 22: 233-240. [DOI:10.3892/or_00000429]
35. Felix A, Nogales FF, Arias-Stella J. Polypoid endometriosis of the uterine cervix with Arias-Stella reaction in a patient taking phytoestrogens. Int J Gynecol Pathol 2010; 29: 185-188. [DOI:10.1097/PGP.0b013e3181b7015e]
36. Shiverick KT, Salafia C. Cigarette smoking and pregnancy I: ovarian, uterine and placental effects. Placenta 1999; 20: 265-272. [DOI:10.1053/plac.1998.0377]

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb